Novo Nordis Outgoing CEO, Lars Frugard JorgenSen, With the increasing pressure of rival Eli Lily, the ban in the Danish Pharmaceutical Monster may be unavoidable as the competition is reduced.
Novo Nordisk, the most valuable European company of $ 50550 billion in Vegvi’s prosperity last year – especially in the United States, is facing an important moment as the market loses the market share and slows down the sales growth.
This year, there is a warning of low -slow growth, with some compounders who have been allowed to produce copycate drugs on the basis of similar ingredients such as Vegovi. Novo Nordisk, who has 000 77,3 employees, according to his website, has reduced its entire year’s sales and profits. He then reduced the value of the market.
The slide is a huge and sudden change for the firm, one of the most popular investment stories in the world, leading to a rapid expansion of production and sales capabilities. Now the company is paying attention to the possible cost reduction measures.
Palanquin
“We may not be able to avoid the ban,” Jorgansen said Danish Broadcaster Dr. “When you have to adjust a company, there are areas where you have fewer people, some (areas) where we must be small.”
He also said that any decision will be taken in the hands of Majiyar Mike Dosdar, the veteran of the company, who took over on Thursday.
On media calls, Jorganesen said that the copycat version of WEG Vegvi’s drug, known as the GLP -1 receptor agonist, was “equal to our business” and the versions of Vegvi’s cycle were sold at the “very low cost points”.
In May, Novo Nordsk said approximately one million American patients were expected to use compound GLP -1 drugs to switch branded treatment after the US Food and Drug Administration. Banning of cyclical copies Vegovi influenced on May 22 and was expected to be a cyclone in the third Third quarter.
However, Finance Chief Carsen Munk Nudson said on Wednesday that more than one million US patients are still using compound GLP -1S and the company’s low Outlook did not cut “compounding” this year.
When asked by what circumstances the company would see in the last six months of the year, “obesity market is unstable,” Nudasen told the analyst. The lower end of the firm’s new full-year guidance category will be for “unpredictable events”, such as the pressure of more than the estimation of the US, he said.
In the same period last year, the lower end of the range was about 150 billion Danish Cron ($ 23 billion) in the late 2025 compared to 157 billion cron ($ 24.5 billion).
Nudson reiterated that the company was taking several strategies against the compounding pharmacy to stop illegal mass compounding.
Jorgensen said the company was encouraged by the latest US prescription data of Vegvi. Earlier this year, the Ranth Lily’s Zapabound overturned the drug in terms of US suggestions, while the lead has declined last month.
The second quarter of the second quarter in the United States has increased by 36 percent, and the outside US market has increased fourfold over a year ago, said Novo Nordisk.
The company is expected to be in the second Half’s second Half’s second Half, due to the large number of sales and exempt from the expected sales from the direct-one consumer or cash-pay channels, while the US prices of Vegovi this quarter are stable.
He said that Novo Nordsk, which started in Novo, is expanding the consumer platform directly from the United States, and in some markets outside the United States, patients with direct insurance vessels may need to be “cash sales” directly.
Cost reduction
After the warning of last week’s profits, Novo Nordisk reiterated his full year’s income expectations on Wednesday.
JorgenSen said the company was “acting to ensure efficiency based on our costs, as they announced that they would end eight research and development projects.
Jeffers analysts said in a letter, “There seems to be a bigger R&D clin-out than usual, but we do not know whether it reflects a strategic reprint or just a coincidence.”
Investors have questioned whether the company will be competitive in the drug market in prosperity. Many equity analysts since last week have reduced their value and the recommendations on stock.
Shares in Novo Nordis last week increased by 30 % – his worst weekly performance in two decades. The stock has been turning to the market since the opening of the market in New York. The pharmaceutical monster came down more than 3.3 per cent by 12 noon (16:00 GMT) at 12 noon.
